Masitinib

Masitinib is a tyrosine kinase inhibitor, a type of drug used in the treatment of certain types of cancer. It is developed by AB Science, a pharmaceutical company based in France.

Masitinib

Mechanism of Action

Masitinib works by inhibiting the activity of certain proteins known as tyrosine kinases. These proteins play a key role in the signaling pathways that control cellular processes such as growth, division, and death. By blocking these proteins, masitinib can help to slow down or stop the growth of cancer cells.

Uses

Masitinib is used in the treatment of certain types of cancer, including gastrointestinal stromal tumors (GISTs), mastocytosis, and some forms of lymphoma. It is also being investigated for use in other conditions, such as Alzheimer's disease, asthma, and multiple sclerosis.

Side Effects

Like all drugs, masitinib can cause side effects. These can include nausea, vomiting, diarrhea, and fatigue. In some cases, it can also cause more serious side effects, such as heart problems, liver damage, and skin reactions.

Development and Approval

Masitinib was developed by AB Science, a pharmaceutical company based in France. It has been approved for use in the European Union and several other countries. However, as of 2021, it has not yet been approved by the Food and Drug Administration (FDA) in the United States.

See Also

• Tyrosine kinase inhibitor
• AB Science
• Gastrointestinal stromal tumor
• Mastocytosis
• Lymphoma

This article is a stub related to pharmacology. You can help WikiMD by expanding it!